Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin

Poupon, L; Lamoine, S; Pereira, V; Barriere, DA; Lolignier, S; Giraudet, F; Aissouni, Y; ... Busserolles, J; + view all Poupon, L; Lamoine, S; Pereira, V; Barriere, DA; Lolignier, S; Giraudet, F; Aissouni, Y; Meleine, M; Prival, L; Richard, D; Kerckhove, N; Authier, N; Balayssac, D; Eschalier, A; Lazdunski, M; Busserolles, J; - view fewer (2018) Targeting the TREK-1 potassium channel via riluzole to eliminate the neuropathic and depressive-like effects of oxaliplatin. Neuropharmacology , 140 pp. 43-61. 10.1016/j.neuropharm.2018.07.026 .

https://ift.tt/2pSUa73